iOmx Therapeutics AG, founded in 2016 and based in Martinsried/Munich, Germany, develops cancer therapeutics focused on next-generation immune checkpoints. The company uses its iOTarg high-throughput screening platform to identify proprietary tumor-associated immune checkpoints and advance a preclinical-stage pipeline. Its lead programs include IMT-07, which targets SIK3, an immune-protective kinase in multiple solid tumors, and IMT-18, a first-in-class antibody designed to inhibit IGSF11 in PD-1/PD-L1-resistant tumors. iOmx was founded on work by Philipp Beckhove, MD, and Nisit Khandelwal, Ph.D., conducted at the German Cancer Research Center and is led by CEO Dr. Apollon Papadimitriou. The company aims to use new funding to advance IMT-07, further develop IMT-18, and continue leveraging iOTarg to move additional novel immune checkpoint programs toward lead candidate stage. iOmx Therapeutics is a biopharmaceutical company developing cancer therapeutics targeting novel immune checkpoints on cancer cells. It uses a proprietary platform that systematically screens tumor cells for specific immune checkpoint modulators to address tumor immune resistance mechanisms. The company intends to advance several proprietary product candidates to initial clinical proof-of-concept. iOmx closed a €40m Series A financing co-led by MPM Capital and Sofinnova Partners, with participation from Wellington Partners and Merck Ventures. Launched in March 2016 by Elmar Maier (CBO) and Sebastian Meier-Ewert (CEO), the company builds on work from scientific founders Philipp Beckhove and Nisit Khandelwal. iOmx is based in Martinsried near Munich, Germany.

Total raised

$120M

Funding rounds

2

Latest round

Series B

Latest activity

Oct 2021